| Name | Title | Contact Details |
|---|---|---|
Heather Lavoie |
Executive Vice President, EBTS and Operations and CIO | Profile |
Damon Becknel |
Director - Information Security | Profile |
Invuity, Inc. is a medical technology company focused on developing and marketing advanced photonics devices to improve the ability of surgeons to illuminate and visualize the surgical cavity during open minimally invasive and minimal access surgery. The company`s patented Intelligent Photonics™ technology enables enhanced surgical precision, efficiency and safety by providing superior visualization. Clinical applications include breast and thyroid oncology, plastic reconstructive, spine, orthopedic, cardiothoracic and general surgery among others. Invuity is headquartered in San Francisco, CA.
Iris Plans provides telehealth Advance Care Planning (ACP) services to health insurers and health care providers, reducing unnecessary care for people with serious medical conditions. ACP lowers the cost of care while improving quality and experience.
Alliance Imaging is a locally owned and managed medical imaging facility that provides advanced imaging services in a safe and comfortable clinic setting. They offer a lower cost of care option and are conveniently located on the south side of St. Cloud.
Phoenix Associates is a Mount Holly, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.